Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 3 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Astellas Institute for Regenerative Medicine has 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 5 distinct examiners, resulting in a distributed prosecution landscape. The workload is spread across 3 distinct art units. O'Neill, Marisol Ann is the busiest examiner and holds 1 pending action.
Because the 5 actions are split among as many examiners, the company must address five different sets of examiner preferences. The concentration in 3 distinct art units provides some technological focus within the broader pharmaceutical field. Practitioners should monitor for consistent themes across the 3 distinct art units while tailoring arguments to the individual examiners.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 3 (50%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| O'NEILL, MARISOL ANN | 1 | 54.5% | +68.2% |
| PYLA, EVELYN Y | 1 | 55.8% | +47.1% |
| WANG, CHANG YU | 1 | 33.4% | +53.7% |
| VIJAYARAGHAVAN, JAGAMYA NMN | 1 | 61.0% | +51.0% |
| TICHY, JENNIFER M.H. | 1 | 64.6% | +34.4% |
| MOSS, NATALIE M | 1 | 30.7% | +17.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16669931 | METHOD OF GENERATING NATURAL KILLER CELLS AND DENDRITIC CELLS FROM HUMAN EMBRYONIC STEM CELL-DERIVED HEMANGIOBLASTS | MOSS, NATALIE M | 8d |
| 18777661 | METHODS FOR PRODUCTION OF PLATELETS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOF | PYLA, EVELYN Y | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16669931 | METHOD OF GENERATING NATURAL KILLER CELLS AND DENDRITIC CELLS FROM HUMAN EMBRYONIC STEM CELL-DERIVED HEMANGIOBLASTS | MOSS, NATALIE M | 8d |
| 18363663 | MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA | VIJAYARAGHAVAN, JAGAMYA NMN | 20d |
| 19104022 | CELL CRYOPRESERVATIVE FORMULATIONS AND METHODS OF USE | O'NEILL, MARISOL ANN | — |
| 18777661 | METHODS FOR PRODUCTION OF PLATELETS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOF | PYLA, EVELYN Y | — |
| 18742929 | METHOD OF DIRECTED DIFFERENTIATION PRODUCING CORNEAL ENDOTHELIAL CELLS, COMPOSITIONS THEREOF, AND USES THEREOF | WANG, CHANG YU | — |
| 17632708 | METHODS OF TREATING VASCULAR DISEASES | TICHY, JENNIFER M.H. | — |
| Art Unit | Apps |
|---|---|
| 1633 | 2 |
| 1653 | 2 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19104022 | CELL CRYOPRESERVATIVE FORMULATIONS AND METHODS OF USE | O'NEILL, MARISOL ANN | 1632 | §102§103§112DP | Non-Final OA | — | Pending | Feb 14, 2025 |
| 18777661 | METHODS FOR PRODUCTION OF PLATELETS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOF | PYLA, EVELYN Y | 1633 | §102§103§112 | Non-Final OA | — | Pending | Jul 19, 2024 |
| 18742929 | METHOD OF DIRECTED DIFFERENTIATION PRODUCING CORNEAL ENDOTHELIAL CELLS, COMPOSITIONS THEREOF, AND USES THEREOF | WANG, CHANG YU | — | §112Other | Non-Final OA | — | Pending | Jun 13, 2024 |
| 18363663 | MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA | VIJAYARAGHAVAN, JAGAMYA NMN | 1633 | §112Other | Non-Final OA | 20d | Pending | Aug 01, 2023 |
| 17632708 | METHODS OF TREATING VASCULAR DISEASES | TICHY, JENNIFER M.H. | 1653 | §112 | Non-Final OA | — | Pending | Feb 03, 2022 |
| 16669931 | METHOD OF GENERATING NATURAL KILLER CELLS AND DENDRITIC CELLS FROM HUMAN EMBRYONIC STEM CELL-DERIVED HEMANGIOBLASTS | MOSS, NATALIE M | 1653 | §103§112 | Final Rejection | 8d | Pending | Oct 31, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAstellas Institute for Regenerative Medicine has 6 pending office actions as of October 2026, spread across 3 art units and 6 examiners.
Marisol Ann O'Neill has the most, with 1 of Astellas Institute for Regenerative Medicine's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
